GS
ADPT icon

GTS Securities’s Adaptive Biotechnologies ADPT Stock Holding History

GTS Securities’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-14,715
Closed -$72.1K – 3780
2023
Q4 		$72.1K Buy
+14,715
New +$67.1K ﹤0.01% 3792

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
AAP
Aristotle Atlantic Partners Sarasota, Florida $2.14B AUM 37.01% 1-Year Est. Return

GTS Securities's ADPT Position: Q1 2024 in Review

GTS Securities sold out of Adaptive Biotechnologies (ADPT) in Q1 2024, closing a stake of 14,715 shares — an estimated $72.1K sold.

GTS Securities first reported a position in ADPT in Q4 2023 and held it in 1 quarter. The position peaked at $72.1K in Q4 2023. 190 funds tracked by Wall St. Rank hold ADPT as of Q1 2024.

  • GTS Securities reported no remaining Adaptive Biotechnologies position as of Q1 2024 after selling out during the quarter.
  • GTS Securities sold 14,715 Adaptive Biotechnologies shares in Q1 2024, an estimated $72.1K.
  • GTS Securities first reported a position in Adaptive Biotechnologies in Q4 2023 and held it in 1 quarter.
  • GTS Securities's Adaptive Biotechnologies position peaked at $72.1K in Q4 2023.
  • 190 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2024.

Based on GTS Securities's 13F filing for Q1 2024, filed 15 May 2024.